Callio Therapeutics is developing novel dual-payload antibody-drug conjugates (ADCs) designed to address resistance to existing cancer therapies, using proprietary linker and ADC platform technologies CLIO-8221 is a first-in-class dual-payload ADC combining a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor, currently in a Phase 1 clinical trial for HER2-expressing solid tumors At AACR 2026, Callio Therapeutics will present preclinical data demonstrating that CLIO-8221 provides a wide therapeutic window with strong durable activity, supporting its potential to deliver clinical benefit in patients with tumors resistant to existing Topo1 inhibitor-based ADCs SEATTLE and SINGAPORE, April 15, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, multi-mechanism approach to cancer treatment, today announced a poster presentation on CLIO-8221 at the American Association of Cancer Research (AACR) Annual Meeting 2026 (April 17-22, San Diego). CLIO-8221, currently being evaluated in an ongoing Phase 1 trial, is a first-in-class dual-payload ADC, engineered for targeted delivery of two payload classes, a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor, to HER2-expressing tumors. "CLIO-8221 is the first program from Callio's dual-payload ADC pipeline to enter the clinic, just one year after our launch, underscoring our commitment to advancing innovative dual-payload ADCs for cancer. By combining two complementary anti-cancer payloads, CLIO-8221 may offer a new treatment option for patients whose cancers are resistant to existing single-payload Topo1 inhibitor-based ADCs," said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer of Callio Therapeutics. "Our preclinical studies support the high potency and enhanced tolerability of CLIO-8221, enabled by our next generation linker platform ... Full story available on Benzinga.com
2026 Copyright © News-Matic.com. All Rights Reserved
